Shionogi & Co., Ltd.

Shionogi & Co., Ltd.

Shionogi & Co., Ltd.

Overview
Date Founded

1919

Headquarters

3-1-8 Dosho-machi,Chuo-Ku,Osaka 541-0045

Type of Company

Public

Employees (Worldwide)

5,233

Industries

Pharmaceuticals
Wholesale: Consumer Non-Durables/Sundries

Company Description

Shionogi & Co., Ltd. engages in the research, development, supply, manufacture, and sale of pharmaceutical products. Its products include prescription drugs, over-the-counter drugs, diagnostic regents, medical devices and others. The company was founded by Gisaburo Shiono on March 17, 1878 and is headquartered in Osaka, Japan.

Executives & Employees

President & Chief Executive Officer

Senior Executive Officer & General Manager-Drug Business

Senior Executive Officer & Head-Tokyo Branch

Senior Executive Officer

Senior Executive Officer

Senior Executive Officer

Senior Executive Officer

Director & Executive Vice President

In-House Counsel

Senior Vice President-CMC R&D Division

Board of Directors

Chairman of the Board, Representative Director at Shionogi & Co., Ltd.

President & Chief Executive Officer at Shionogi & Co., Ltd.

President at The Osaka Chamber of Commerce & Industry

President & Representative Director at Ginsen Co., Ltd.

Former Chairman at Osaka Gas Co., Ltd.

Senior Executive Officer, Chief Director of Business Strategy, Director at Shionogi & Co., Ltd.

Partner at Oh-Ebashi LPC & Partners

Paths to Shionogi & Co., Ltd.
Potential Connections via
Relationship Science
You
Shionogi & Co., Ltd.
Owners & Shareholders
Details Hidden

NAM-J's investment philosophy has core elements including: active management focusing on fundamental research; a team approach; and thorough risk/return assessment. They offer a broad range of equity strategies, including core, value, and growth. The investment approach of the core strategy combines a bottom-up, relative value approach with rigorous fundamental research on individual stocks and a top-down overlay. The investment process is designed to add value in all market conditions over a medium- to long-term horizon. For value, they use bottom-up approach without sector constraints where the quality of stock selection is paramount. The investment process is based on a combination of rigorous quantitative screening based on valuation factors with liquidity consideration and qualitative analysis on firms' fundamentals. The growth strategy focuses on ROE level and sustainability and fundamental strength. In conducting NAM-J's investment decisions, they utilize a broad spectrum of information, including financial publications, third-party research materials, annual reports, prospectuses, regulatory filings, company press releases, corporate rating services, inspections of corporate activities and meetings with management of various companies.

Details Hidden

AMO seeks to help customers build assets in the long term and aims to provide global asset management by quickly responding to constantly changing market circumstances and regulatory trends. The firm seeks to efficiently predict socioeconomic or market changes in order to identify appropriate asset management-based solutions.

Details Hidden

SMTAM's fund managers of their respective investment departments implement investments in line with the investment plans and manage funds. The general managers of their respective investment departments check the status of investment implementations carried out by the fund managers thereof. Execution of buy or sell orders is carried out by traders at the Trading Department which is independent of the respective investment departments, based on execution instructions for investments from the respective investment departments. The firm leverages the strengths, operational structure, know-how and network of their parent company to manage assets, utilizing bottom-up and top-down quantitative investment styles to make investments through their range of funds.

Recent Transactions
Details Hidden

Shionogi & Co., Ltd. purchases Pionnier KK from Nippon Venture Capital Corp., SMBC Venture Capital KK

Details Hidden

Shionogi & Co., Ltd., Shionogi Healthcare & Co., Ltd. purchase Takara Bio, Inc. /Health Food Business from Takara Bio Inc.

Details Hidden

Rohto Pharmaceutical Co., Ltd. purchases Shionogi Healthcare & Co., Ltd. from Shionogi & Co., Ltd.

Transaction Advisors
Legal Advisor

Advised onShionogi & Co., Ltd. purchases C&O Pharmaceutical Technology (Holdings) Ltd. from Leo Star Development Ltd.

Investment Advisor

Advised onShionogi & Co., Ltd. purchases Shionogi Pharma, Inc.

Legal Advisor

Advised onShionogi & Co., Ltd. purchases Shionogi Pharma, Inc.

Legal Advisor

Advised onShionogi & Co., Ltd. purchases Shionogi Pharma, Inc.

Legal Advisor

Advised onShionogi & Co., Ltd. purchases Shionogi Pharma, Inc.

Associate, Corporate Team

Advised onShionogi & Co., Ltd. purchases Shionogi Pharma, Inc.

Advisors & Consultants
Legal Advisor

Skadden, Arps, Slate, Meagher & Flom LLP

Legal Advisor

Partner at Finnegan, Henderson, Farabow, Garrett & Dunner LLP

Clients

Johnson & Johnson is a holding company, which engages in the research and development, manufacture and sale of products in the health care field. It operates through the following segments: Consumer, Pharmaceutical, and Medical Devices. The Consumer segment includes products used in the baby care, oral care, beauty, over-the-counter pharmaceutical, women's health, and wound care markets. The Pharmaceutical segment focuses on therapeutic areas such as immunology, infectious diseases ad vaccines, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension. The Medical Devices segment offers products used in the orthopedic, surgery, cardiovascular, diabetes care, and eye health fields. The company was founded by Robert Wood Johnson I, James Wood Johnson and Edward Mead Johnson Sr. in 1886 and is headquartered in New Brunswick, NJ.

GlaxoSmithKline Plc is a global healthcare company which engages in researching, developing and manufacturing of pharmaceutical medicines, vaccines and consumer healthcare products. It operates through the following four segments: Pharmaceuticals, Pharmaceuticals R&D, Vaccines and Consumer Healthcare. The Pharmaceuticals segment researches, develops and makes available medicines that treat a variety of serious and chronic diseases. The Vaccines segment produces pediatric and adult vaccines to prevent a range of infectious diseases including, hepatitis A and B, diphtheria, tetanus and whooping cough, measles, mumps and rubella, polio, typhoid, influenza and bacterial meningitis. The Consumer Healthcare segment markets a range of consumer health products based on scientific innovation. The company was founded in 1715 and is headquartered in Brentford, the United Kingdom.

Pfizer Inc. engages in the discovery, development, and manufacture of healthcare products specializes in medicines, vaccine, and consumer healthcare. It operates through the Pfizer Innovative Health (IH) and Pfizer Essential Health (EH) segments. The IH segment focuses on the development and commercializing medicines and vaccines for internal medicine, oncology, inflammation and immunology, rate disease, and consumer healthcare. The EH segment is involved in development and supply of branded generics, generic sterile injectable products, biosimilars, and select branded products including anti-infectives. The company was founded by Charles Pfizer Sr. and Charles Erhart in 1849 and is headquartered in New York, NY.

Key Stats and Financials As of 2019
Market Capitalization
$1.93T
Total Enterprise Value
$1.84T
Earnings Per Share
$424.31
Revenue
$364B
Net Profit
$133B
EBITDA
$158B
EBITDAMargin
43.37%
Total Debt
$1.8B
Total Equity
$672B
Enterprise Value Sales
5.06x
Enterprise Value EBITDAOperating
11.68x
TEVNet Income
13.87x
Debt TEV
0x
Three Year Compounded Annual Growth Rate Of Revenue
5.47%
Five Year Compounded Annual Growth Rate Of Revenue
4.65%
Investments
Details Hidden

Anthera Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in the development and commercialization of medicines to treat serious and life threatening diseases. It offers Sollpura and blisibimod to treat diseases such as exocrine pancreatic insufficiency and Immunoglobulin A nephropathy. The company was founded by Paul F. Truex on September 9, 2004 and is headquartered in Hayward, CA.

Details Hidden

Enanta Pharmaceuticals, Inc. is a research and development-focused biotechnology company. It engages in the research and development of molecule drugs for the treatment of viral infections and liver diseases. Its brands include Mavyret and Viekira Pak. The company was founded by Peter O. Kliem and Gregory L. Verdine in 1995 and is headquartered in Watertown, MA.

Suppliers
OncoTherapy Science, Inc. Pharmaceuticals | Kawasaki, KN

OncoTherapy Science, Inc. engages in the research and development of pharmaceutical products. It focuses its research on cancer-related cells and genes, and develops cancer therapy products which include low molecular drugs, antibody drugs, cancer peptide vaccine, and diagnostic medicine and nucleic acid drugs. The company was founded on April 6, 2001 and is headquartered in Kawasaki, Japan.

Shire Plc Wholesale: Consumer Non-Durables/Sundries | Dublin, DU

Shire Plc is a biopharmaceutical company, which engages in the research, development, licensing, manufacturing, marketing, distribution, and sale of medicines. Its products include adderall, advate, adynovate, agrylin, antithrombin 3, aralast, bebulin, buccolam, feiba, firazyr, and foznol. The company was founded in 1986 and is headquartered in Dublin, Ireland.

BioCryst Pharmaceuticals, Inc. Medical Support Services | Birmingham, Alabama

Founded in 1986, BioCryst has approximately 38 employees between the Company’s headquarters in Durham, North Carolina and its Discovery Center of Excellence in Birmingham, Alabama. With expertise in drug discovery, clinical development and regulatory affairs, we continue to advance our clinical programs and to generate new compounds from our own discovery engine. We are proud of our culture of engagement and accountability that rewards people for innovative thinking and achievement of key objectives. The commitment of BioCryst has remained unchanged. We continue to be passionate about advancing novel therapeutics for patients with serious diseases.

This web site is not endorsed by, directly affiliated with, maintained, authorized, or sponsored by Shionogi & Co., Ltd.. The use of any trade name or trademark is for identification and reference purposes only and does not imply any association with the trademark holder. The Presence of Shionogi & Co., Ltd.'s profile does not indicate a business or promotional relationship of any kind between RelSci and Shionogi & Co., Ltd..
  • be_ixf; php_sdk; php_sdk_1.4.15
  • https://relationshipscience.com/organization/shionogi-and-co-ltd-267770
  • https://relationshipscience.com/organization/shionogi-and-co-ltd-267770